For anyone that doesnt think DR. Hidalgo is PMCB's ace in the hole just look at what he has done at the other company he held a stock position in. He is an eye on the latest and greatest things in biotech and PMCB has one of them. He is top in his field and he loves PMCB. Why do you think he designed the PMCB trial ? Why do you think he is the PI of the PMCB trial???? Do you think he believes in PMCB's treatment well just look at his actions not even his words. Oh also look at his ownership in PMCB and his other one that just did a major deal with a company that he sits on the board lol I wont mention the name but its easy to find it. Once the IND gets the thumbs up which we now know what the NEW COVID FDA wants for our trial it will happen 1 step at a time. Above $10.00 I can show this to many hedge funds and they are all looking for the next best way to treat Cancer let alone Pancreatic Cancer.
Manuel Hidalgo, M.D., Ph.D., is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Dr. Hidalgo received his M.D. from the University of Navarra in Pamplona, Spain in 1992, and Ph.D. from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital "12 de Octubre" in Madrid and at the University of Texas Health Science Center in San Antonio, Texas. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio. Prior to this position, he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to serve as Director of the Gastrointestinal Oncology Program at the Kimmel Comprehensive Cancer Center, where he also held the title of Associate Professor of Oncology. Dr. Hidalgo became Director of the Clinical Research Program at the Spanish National Cancer Center in 2009 and Vice Director of Translational Research in 2011. In 2015, he became the Chief of the Division of Hematology and Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. Dr. Hidalgo also served as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the use of Avatar mouse models for cancer research and recently contributed to the development and Federal Drug Administration (FDA) approval of nab-paclitaxel for pancreatic cancer treatment. Dr. Hidalgo’s current research focuses on strategies for personalized medicine and immunotherapy in pancreatic cancer. Dr. Hidalgo also serves on the Board of Directors for Bristol Myers Squibb (BMS).
